公开(公告)号：US20240352083A1

公开(公告)日：2024-10-24

申请号：US18647911

申请日：2024-04-26

申请人： UCB Biopharma SRL

发明人： Ralph Adams ,  Terence Seward Baker ,  Xiaofeng Liu

IPC分类号： C07K14/54 ,  C07K14/505 ,  C07K14/535 ,  C07K14/55 ,  C07K16/18 ,  C07K16/24 ,  C07K16/28

CPC分类号： C07K14/5443 ,  C07K14/505 ,  C07K14/535 ,  C07K14/5428 ,  C07K14/55 ,  C07K16/18 ,  C07K16/244 ,  C07K16/248 ,  C07K16/2809 ,  C07K16/2818 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/567 ,  C07K2317/569 ,  C07K2317/622 ,  C07K2317/76

摘要： The present invention provides antibodies comprising a variable (V) domain and an insert polypeptide, wherein the insert polypeptide is within the framework 3 region of the V domain.

公开(公告)号：US20240327476A1

公开(公告)日：2024-10-03

申请号：US18634220

申请日：2024-04-12

申请人： ModernaTx, Inc.

发明人： Antonin DE FOUGEROLLES ,  Justin GUILD

IPC分类号： C07K14/47 ,  A61K9/00 ,  A61K9/127 ,  A61K9/14 ,  A61K9/50 ,  A61K9/51 ,  A61K31/7088 ,  A61K31/7115 ,  A61K38/00 ,  A61K38/17 ,  A61K38/18 ,  A61K38/19 ,  A61K38/21 ,  A61K38/36 ,  A61K38/44 ,  A61K38/45 ,  A61K38/48 ,  A61K39/395 ,  A61K47/10 ,  A61K47/34 ,  A61K47/54 ,  A61K48/00 ,  C07K14/005 ,  C07K14/435 ,  C07K14/475 ,  C07K14/485 ,  C07K14/505 ,  C07K14/515 ,  C07K14/525 ,  C07K14/535 ,  C07K14/56 ,  C07K14/565 ,  C07K14/62 ,  C07K14/705 ,  C07K14/745 ,  C07K14/75 ,  C07K16/00 ,  C07K16/28 ,  C07K16/32 ,  C07K19/00 ,  C12N9/00 ,  C12N9/02 ,  C12N9/10 ,  C12N9/16 ,  C12N9/24 ,  C12N9/42 ,  C12N9/64 ,  C12N9/88 ,  C12N15/11 ,  C12N15/52 ,  C12N15/67 ,  C12N15/85 ,  C12N15/87 ,  C12N15/88 ,  C12P13/04 ,  C12P21/00

CPC分类号： C07K14/47 ,  A61K9/1271 ,  A61K9/1272 ,  A61K9/1277 ,  A61K9/14 ,  A61K9/145 ,  A61K9/5031 ,  A61K9/5123 ,  A61K9/5146 ,  A61K9/5153 ,  A61K31/7088 ,  A61K31/7115 ,  A61K38/17 ,  A61K38/1767 ,  A61K38/177 ,  A61K38/1816 ,  A61K38/1866 ,  A61K38/1891 ,  A61K38/191 ,  A61K38/193 ,  A61K38/212 ,  A61K38/215 ,  A61K38/36 ,  A61K38/363 ,  A61K38/44 ,  A61K38/45 ,  A61K38/4833 ,  A61K38/4846 ,  A61K39/3955 ,  A61K47/10 ,  A61K47/34 ,  A61K47/54 ,  A61K47/542 ,  A61K47/543 ,  A61K48/0033 ,  A61K48/005 ,  A61K48/0066 ,  A61K48/0075 ,  C07K14/005 ,  C07K14/435 ,  C07K14/4705 ,  C07K14/4713 ,  C07K14/485 ,  C07K14/505 ,  C07K14/515 ,  C07K14/525 ,  C07K14/535 ,  C07K14/56 ,  C07K14/565 ,  C07K14/62 ,  C07K14/705 ,  C07K14/745 ,  C07K14/75 ,  C07K16/00 ,  C07K16/2887 ,  C07K16/32 ,  C07K19/00 ,  C12N9/0069 ,  C12N9/1051 ,  C12N9/16 ,  C12N9/2402 ,  C12N9/2445 ,  C12N9/644 ,  C12N9/6451 ,  C12N9/88 ,  C12N9/93 ,  C12N15/11 ,  C12N15/52 ,  C12N15/67 ,  C12N15/85 ,  C12N15/87 ,  C12N15/88 ,  C12P13/04 ,  C12P21/00 ,  C12P21/005 ,  C12Y113/12007 ,  C12Y304/21005 ,  C12Y603/02019 ,  A61K9/0019 ,  A61K38/00 ,  A61K48/00 ,  C07K14/475 ,  C12N2840/00 ,  C12N2840/85 ,  C12Y304/21022

摘要： The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides, primary transcripts and mmRNA molecules.

公开(公告)号：US20240287150A1

公开(公告)日：2024-08-29

申请号：US18572549

申请日：2022-06-24

申请人： PRESIDENT AND FELLOWS OF HARVARD COLLEGE

发明人： Jungmin LEE ,  Jeffrey WAY

IPC分类号： C07K14/505 ,  A61K38/00 ,  C07K16/28

CPC分类号： C07K14/505 ,  C07K16/2896 ,  A61K38/00 ,  C07K2317/569 ,  C07K2317/622 ,  C07K2319/00

摘要： The technology described herein is directed to engineered polypeptides comprising an anti-GYPA antibody reagent and an EPO polypeptide, such as an EPO polypeptide that is engineered to be tissue-protective. Further provided herein are methods of treating a neurodegenerative disease or disorder, hypoxic tissue damage, traumatic brain injury, or stroke by administering said polypeptides.

公开(公告)号：US11993630B2

公开(公告)日：2024-05-28

申请号：US17145653

申请日：2021-01-11

申请人： Hoffmann-La Roche Inc.

发明人： Roberto Falkenstein ,  Bernhard Spensberger

IPC分类号： C07K1/16 ,  B01D15/26 ,  B01D15/36 ,  C07K1/18 ,  C07K14/505

CPC分类号： C07K1/18 ,  B01D15/362 ,  C07K14/505

摘要： Herein is reported a method for the purification of a protein comprising erythropoietin and a single poly (ethylene glycol) residue from reaction by-products or not reacted starting material by a cation exchange chromatography method. It has been found that by employing a cation exchange Toyopearl® SP-650 chromatography material and employing a second wash step with an increased pH value compared to the first wash step a fusion protein of erythropoietin and a single poly (ethylene glycol) residue can be obtained in a single step with high purity and yield and suitability for large scale applications.

公开(公告)号：US20230374095A1

公开(公告)日：2023-11-23

申请号：US18309982

申请日：2023-05-01

申请人： Box, Inc.

发明人： Rohit Bakshi ,  Daniel Wayne Morkovine ,  Faizan N. Buzdar

IPC分类号： C07K14/59 ,  C07K14/505 ,  C07K14/555 ,  C07K14/575 ,  C07K14/61 ,  C12N9/64 ,  C12N15/85 ,  G06Q10/0633 ,  G06Q10/0637 ,  G06Q10/0639 ,  G06Q30/0201

CPC分类号： C07K14/59 ,  C07K14/505 ,  C07K14/555 ,  C07K14/575 ,  C07K14/61 ,  C12N9/6437 ,  C12N9/644 ,  C12N15/85 ,  G06Q10/0633 ,  G06Q10/0637 ,  G06Q10/06393 ,  G06Q30/0201 ,  A61K38/00

摘要： Methods, systems and computer program products for shared content management systems that provide performance analytics pertaining to a project. Embodiments include establishing one or more network communication links between a content management system that manages a plurality of shared content objects and a plurality of applications that cause modifications to the shared content objects in accordance with workflows of the project. Iteraction events that correspond to modifications over the shared content objects are recorded such that interaction events associated with the plurality of applications are selected based at least in part on attributes associated with the interaction events. Relationships between the recorded interaction events such as time durations between certain of the interaction events are calculated. Project performance measurements are generated based on the calculations and/or based on other relationships between the interaction events. The calculations may span across many different applications and/or many different departments and/or many different enterprises.

公开(公告)号：US11820807B2

公开(公告)日：2023-11-21

申请号：US15177605

申请日：2016-06-09

申请人： UBI Pharma Inc ,  Chang-Yi Wang

发明人： Chang-Yi Wang ,  Wen-Jiun Peng ,  Wei-Ting Kao

IPC分类号： C07K14/705 ,  C07K14/745 ,  C07K19/00 ,  C07K14/565 ,  C07K14/505 ,  C07K14/535 ,  C07K14/56 ,  C07K14/57 ,  C12N9/64

CPC分类号： C07K14/745 ,  C07K14/505 ,  C07K14/535 ,  C07K14/56 ,  C07K14/565 ,  C07K14/57 ,  C07K19/00 ,  C07K2317/53 ,  C07K2319/03 ,  C12N9/644

摘要： A fusion protein is disclosed. The fusion protein of the invention comprises an Fc fragment of an immunoglobulin G and a bioactive molecule, wherein the Fc is a single chain Fc. The amino acids in the hinge of the Fc is mutated, substituted, or deleted so that the hinge of Fc cannot form disulfide bonds. Methods for producing and using the fusion protein of the invention are also provided.

公开(公告)号：US20230272011A1

公开(公告)日：2023-08-31

申请号：US18018208

申请日：2021-07-30

申请人： Avacta Life Sciences Limited

发明人： Emma Jenkins ,  Estelle Adam ,  Emma Stanley ,  Amrik Basran ,  Matthew P. Vincent ,  Bruno Gomes

IPC分类号： C07K14/00 ,  C07K14/575 ,  C07K14/505 ,  C07K14/605 ,  C12N15/70

CPC分类号： C07K14/001 ,  C07K14/57545 ,  C07K14/505 ,  C07K14/605 ,  C12N15/70 ,  C07K2319/00 ,  C12N2800/101

摘要： Provided herein, in some embodiments, are recombinantly engineered variant of stefin polypeptides (AFFIMER® polypeptides) that binds to human serum albumin and extends the half-life of the polypeptides. Also provided herein, in some embodiments, are composition containing the polypeptides, methods of using the polypeptides, and methods of producing the polypeptides.

公开(公告)号：US20230242573A1

公开(公告)日：2023-08-03

申请号：US17990478

申请日：2022-11-18

申请人： UBIPROTEIN, CORP.

发明人： Kyunggon Kim ,  Kwang-Hyun Baek ,  Sung-Ryul Bae ,  Myung-Sun Kim ,  Hyeonmi Kim ,  Yeeun Yoo ,  Lan Li ,  Jung-Hyun Park ,  Jin-Ok Kim

IPC分类号： C07K1/107 ,  C07K14/49 ,  C07K14/505 ,  C07K14/575 ,  C07K16/00 ,  C07K14/535 ,  C07K14/565 ,  C07K14/51 ,  C07K14/50 ,  C07K14/605 ,  C07K14/61 ,  C07K14/62 ,  C07K14/56 ,  A61K38/00

CPC分类号： C07K1/1075 ,  C07K14/49 ,  C07K14/505 ,  C07K14/5759 ,  C07K16/00 ,  C07K14/535 ,  C07K14/565 ,  C07K14/51 ,  C07K14/50 ,  C07K14/605 ,  C07K14/61 ,  C07K14/62 ,  C07K14/56 ,  C07K14/575 ,  A61K38/00 ,  C07K2317/94 ,  C07K2317/40

摘要： The present invention relates to a method for prolonging half-life of a protein or a (poly)peptide by replacing one or more amino acid residues of the protein. Further, the present invention is about the protein having a prolonged half-life prepared by the method above.

公开(公告)号：US20230151071A1

公开(公告)日：2023-05-18

申请号：US17917264

申请日：2021-04-09

申请人： UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS ,  UNIVERSITY OF SOUTH DAKOTA

发明人： Samuel Newton Sathyanesan ,  Monica Sathyanesan ,  Jason Petersen

IPC分类号： C07K14/505 ,  A61P25/28

CPC分类号： C07K14/505 ,  A61P25/28 ,  A61K38/00

摘要： Disclosed are polypeptides comprising an engineered recombinant EPO. For example, disclosed are polypeptides comprising the sequence of SEQ ID NO: 1. Disclosed are variant Epo polypeptides comprising three amino acid substitutions at positions 20, 45 and 97 of wild type human Epo. Disclosed are polynucleotides comprising a nucleic acid capable of encoding one or more of the disclosed polypeptides. Disclosed are vectors comprising any of the polynucleotides disclosed herein. Disclosed are compositions comprising the disclosed polypeptides, polynucleotides or vectors. Disclosed are cells comprising one or more of the disclosed polypeptides, one or more of the disclosed polynucleotides, and/or one or more of the disclosed vectors. Disclosed are methods of using a therapeutically effective amount of one or more of the disclosed polypeptides, nucleic acids or vectors to a subject in need thereof.

公开(公告)号：US20190241633A1

公开(公告)日：2019-08-08

申请号：US16098844

申请日：2017-05-04

申请人： CureVac AG

发明人： Mariola FOTIN-MLECZEK ,  Ingmar HOERR

IPC分类号： C07K14/505

CPC分类号： C07K14/505 ,  A61K31/7088 ,  A61K38/00 ,  A61K48/00 ,  A61K48/005

摘要： The present invention relates to an RNA encoding a therapeutic protein. In particular, the present invention relates to RNA suitable for use as a medicament. The present invention concerns such novel RNA as well as compositions and kits comprising the RNA. Furthermore, the present invention relates to the RNA, compositions or kits as disclosed herein for use as a medicament. The present invention also provides the use of the RNA, compositions or kits as disclosed herein far increasing the expression of said encoded protein, in particular in gene therapy.